Amphilix AG
Targeted radiopharmaceutical for the treatment of cancer
Amphilix and the Paul Scherrer Institute (ETH Zürich) have teamed up to make a new radioligand for the treatment of cancers with high unmet medical need. The drug target is highly expressed in both cancer cells and growing blood vessels within the tumor. We have demonstrated selective tumor uptake of the radioligand in a mouse xenograft model.
Only registered users have access to funding information.
Please log in or register to continue. Registration is free.
No news
No milestones
No Jobs
No videos and documents
No Awards
Amphilix AG
Targeted radiopharmaceutical for the treatment of cancer
Website:
www.amphilix.com/
Headquarter:
Bettingen
Foundation Date:
July 2020
Technology:
- Biotech
Sectors:
- Biotech
- Cancer
- Drug discovery
- Imaging and Radiology
- Research and development
- Small molecule drugs